Inhibition of natural killer cell activity in mice treated with tobacco specific carcinogen nnk

Journal of Toxicology and Environmental Health - Part A

Volumn 56, Issue 2, 1999, Pages 131-144

  Goud, S Niranjan ^a   Kaplan, Alan M ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; CORTISONE; INTERLEUKIN 12; POLYINOSINIC POLYCYTIDYLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVITY; CELL COUNT; CELL MEDIATED CYTOTOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; INTRAPERITONEAL DRUG ADMINISTRATION; ISOTOPE LABELING; LUNG ALVEOLUS CELL; LYMPH NODE CELL; MELANOMA CELL; METASTASIS POTENTIAL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR CELL; TUMOR IMMUNITY;

ANIMALS; BIOLOGICAL RESPONSE MODIFIERS; CARCINOGENS; CORTISONE; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INTERLEUKIN-12; KILLER CELLS, NATURAL; LUNG NEOPLASMS; LYMPHOCYTE SUBSETS; MELANOMA; MICE; NEOPLASMS, EXPERIMENTAL; NITROSAMINES; POLY I-C; TUMOR CELLS, CULTURED;

ANIMALIA; NICOTIANA TABACUM;

EID: 0033593417     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/009841099158196     Document Type: Article

References (33)

1. Anderson, L. M., Hecht, S. S., Dixon, D. E., Dove, L. F., Kovatch, R. M., Amin, S., Hoffmann, D., and Rice, J. M. 1989. Evaluation of the transplacental tumorigenicity of the tobacco specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in mice. Cancer Res. 49:3770-3775.
2. Belinsky, S. A., White, C. M., Devereux, T. R., Swenberg, J. A., and Anderson, M. W. 1987. Cell selective alkylation of DNA in rat lung following low dose exposure to the tobacco specific carcinogen 4-(N-methyl-N-nitrosamino-1-(3-pyridyl)-1-butanone. Cancer Res. 47:1143-1148.
3. s-methylguanine formation in Clara cells and induction of pulmonary neoplasia in the rat by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res. 50: 3772-3780.
4. Brunda, M. J. 1994. Interleukin-12. J. Leukocyte Biol. 55:280-288.
5. Brunda, M. J., Herberman, R. B., and Holden, H. T. 1980. Inhibition of murine natural killer cell activity by prostaglandins. J. Immunol. 124:2682-2687.
6. Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., and Gately, M. K. 1993a. Antitumor and antimetastatic activity of interleukin-12against murine tumors. J. Exp. Med. 178:1223-1230.
7. Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Wolf, S. F., and Gately, M. K. 1993b. Antitumor activity of interleukin-12in murine tumor models. Proc. Am. Assoc. Cancer Res. 34:464 (abstr.).
8. Bussiere, J. L., Mather, G. G., and Exon, J. H. 1991. Effect of cyclosporine on 3-methylcholanthrene induced carcinogenesis and immune responses in the rat. Immunobiology 182:205-215.
9. Devereuex, T. R., Anderson, M. W., and Belinsky, S. A. 1991. Role of ras protooncogene activation in the formation of spontaneous and nitrosamine induced lung tumors in the resistant C3H mouse. Carcinogenesis 12:299-303.
10. Djeu, J., Heinbaugh, J., Holden, H., and Herberman, R. 1979. Augmentation of mouse natural killer cell activity by interferon and interferon i nducers. J. Immunol. 122:175-181.
11. Doll, R., and Peto, R. 1981. The cause of cancer: Quantitative estimates of the avoidable risks of cancer in the United States today. JNCI 55:1191-1308.
12. Ferson, M., Edwards, A., Lind, A., Milton, G. W., and Hersey, P. 1979. Low natural killer cell activity and immunoglobulin levels associated with smoking in human subjects. Int. J. Cancer23:603-609.
13. Gorelik, E., and Herberman, R. B. 1981. Inhibition of the activity of mouse natural ki ller cells by urethane. JNCI 66:543-548.
14. Goud, S. N., Kaplan, A. M., and Subbarao, B. 1990. Primary antibody responses to thymus independent antigens in the lungs and hilar l ymph nodes of mice. Infect. Immun. 58:2035-2041.
15. Goud, S. N., Kaplan, A. M., and Subbarao, B. 1992. Effects of cigarette smoke on the antibody responses to thymic independent antigens from different lymphoid tissues of mice. Arch. Toxicol. 66:164-169.
16. Goud, S. N., Zhang, L., and Kaplan, A. M. 1993. Immunostimulatory potential of smokeless tobacco extract in in vitro cultures of murine l ymphoid tissues. Immunopharmacology 25:95-105.
17. Hecht, S. S., and Hoffmann, D. 1989. The relevance of tobacco specific nitrosamines to human cancer. Cancer Surgery 8:273-294.
18. Hecht, S. S., Morse, M. A., Amin, S., Stoner, G. D., Jordan, K. G., Choi, C. I., and Chung, F. L. 1989. Rapid single dose model for lung tumor induction in A/J mice by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and the effect of diet. Carcinogenesis 10:1901-1904.
19. Herberman, R. B., and Ortaldo, J. R. 1981. Natural killer cells: Their role in defenses against disease. Science 214:24-30.
20. Hochman, P. S., and Cudkowicz, G. 1979. Suppression of natural cytotoxicity by spleen cells of hydrocortisone treated mice. J. Immunol. 123:968-976.
21. Hoffmann, D., and Hecht, S. S. 1990. Advances in tobacco carcinogenesis. In Handbook of experimental pharmacology, vol. 94, pp. 63-102. New York: Springer-Verlag.
22. Hoffmann, D., Brunnemann, K. D., Prokopczyk, B., and Djordjevic, M. V. 1994. Tobacco specific N-nitrosamines and areca derived N-nitrosamines: Chemistry, biochemistry, carcinogenicity, and relevance to humans. J. Toxicol. Environ. Health 41:1-52.
23. International Agency for Research on Cancer. 1986. Tobacco smoking. IARCMonogr. Eval. Carcinogen. Risk Chem. Hum. 38:1-421.
24. Luster, M. I., Germolec, D. R., Burleson, G. R., Jameson, C. W., Ackermann, M. F., Lamm, K. R., and Hayes, H. T. 1987. Selective i mmunosuppression in mice of natural killer cell activity by ochra-toxin A. Cancer Res. 47:2259-2263.
25. Moore, J. A., Huff, J. E., and Dean, J. H. 1982. The National Toxicology Program and immunological toxicology. Pharmacol. Rev. 34:13-16.
26. Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schreiber, R. D., Storkus, W. J., and Lotze, M. T. 1994. Recombinant IL-12administration induces tumor regression in association with IFN-y production. J. Immunol. 153: 1697-1706.
27. Naume, B., Gately, M. K., and Espevik, T. 1992. A comparative study of IL-12(cytotoxic l ymphocyte maturation factor), IL-2and IL-7 induced effects on immunomagnetically purified CD56+ NK cells. J. Immunol. 148:2429-2436.
28. Newman, L. S., Kreiss, K., and Campbell, P. A. 1991. Natural killer cell tumorlcldal activity In cigarette smokers and in silicotics. Clin. Immunol. Immunopathol. 60:399-411.
29. Riccardi, C., Santoni, A., Barlozzari, T., Puccetti, P., and Herberman, R. 1980. In vivo natural reactivity of mice against tumor cells. Int. J. Cancer 25:475-486.
30. Rodenhuis, S., and Slebos, R. J. C. 1992. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res. Suppl. 52:2665-2669.
31. Tollerud, D. J., Clark, J. W., Brown, L. M., Neuland, C. Y., Mann, D. L., Pankiw-Trost, L. K., Blattner, W. A., and Hoover, R. N. 1989. Association of cigarette smoking with decreased numbers of circulating natural killer cells. Am. Rev. Respir. Dis. 139:194-198.
32. U.S. Department of Health and Human Services. 1984. The Health Consequences of Smoking: Chronic Obstructive Lung Disease. A Report of the Surgeon General. Washington, DC: Government Printing Office. Publication no. DHHS (PHS) 84-50205.
33. U.S. Surgeon General. 1987. The Health Consequences of Smoking—The Health Consequences of Involuntary Smoking. Rockville, MD: DHHS (CDC) 87-8398.